Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy.

Trial Profile

Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2013

At a glance

  • Drugs Cetuximab (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT
  • Sponsors Eli Lilly; ImClone Systems
  • Most Recent Events

    • 11 Nov 2013 Results published in Lancet Oncology.
    • 11 Jun 2012 Status changed from active, no longer recruiting to completed.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top